ReNetX Bio launches with chronic SCI candidate

Neurology newco ReNetX Bio (New Haven, Conn.) launched July 24 and announced the start of a series A round to fund its first Phase I/II trial of Nogo Trap, the company’s lead candidate to treat chronic spinal cord injury. The company is also exploring the candidate in acute spinal cord injury and glaucoma.

The newco has rights to Nogo Trap from Yale University (New Haven, Conn.). The product is a decoy receptor that binds growth inhibitors found in CNS tissue that limit axonal sprouting and regeneration...